Article Text

Download PDFPDF
c-myc Amplifications in primary breast carcinomas and their local recurrences
  1. S Aulmann1,
  2. N Adler1,
  3. J Rom2,
  4. B Helmchen1,
  5. P Schirmacher1,
  6. H P Sinn1
  1. 1Department of Pathology, University of Heidelberg, Heidelberg, Germany
  2. 2Department of Gynaecology and Obstetrics, University of Heidelberg
  1. Correspondence to:
    Dr S Aulmann
    Department of Pathology, University of Heidelberg, Im Neuenheimer Feld 220/221, 69120 Heidelberg, Germany; sebastian_aulmann{at}


Objective: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas.

Methods: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation.

Results: 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients.

Conclusions: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.

  • FISH, fluorescence in situ hybridisation
  • IRS, immunoreactivity scores
  • UICC, International Union against Cancer
  • breast cancer
  • c-myc
  • fluorescence in situ hybridisation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.